Lucius: Use only the official anti-counterfeiting website and beware of counterfeit LuciTir

Recently, Lao Lucius Pharmaceutical (Lucius Pharmaceuticals) issued a solemn statement regarding counterfeit products bearing its brand and imitation anti-counterfeiting websites appearing on the market. Unscrupulous individuals have set up fake anti-counterfeiting verification websites in an attempt to mislead consumers, and the company has initiated rights protection procedures in this regard.

Use only the unique anti-counterfeiting domain, and beware of the "two v" counterfeit trap

Consumers need to pay special attention to URL details when verifying product authenticity:

Official genuine product anti-counterfeiting query website: cc.wkfw318.com (in the domain, "wkfw" is followed by one letter "w")

Counterfeit anti-counterfeiting website: cc.wkfw318.com (in the domain, "wkfw" is followed by two letters "v")

It is worth noting that these two URLs are visually extremely similar. Unscrupulous individuals exploit the similar shapes of the letter "w" and "vv" to confuse viewers.

Lucius Pharmaceuticals emphasizes that the anti-counterfeiting code website is the only credential for verifying genuine Lao Lucius products. Consumers are urged to stay vigilant when purchasing, distinguish carefully, rely on the official anti-counterfeiting domain, and verify the URL before entering the anti-counterfeiting code. If counterfeit products or fake anti-counterfeiting websites are found, evidence should be retained for rights protection. The company specifically warns: injecting counterfeit products poses major risks.

The development path of Lao Lucius

Lao Lucius Pharmaceutical Co., Ltd. is located in Vientiane, the capital of Laos, and is a legitimate pharmaceutical enterprise approved by the Lao government.

In 2020, Lucius Pharmaceuticals assembled a top-tier R&D team and a modern operations team to provide safe, effective, and reasonably priced medicines to patients worldwide. The company's factory covers an area of approximately 210,000 square meters. It built the Asia-Pacific No. 1 Smart Factory, introduced advanced pharmaceutical equipment from China, the United States, Germany, and other countries, and obtained GMP certification issued by the Lao Ministry of Health.

In terms of product lines, as of June 2024, Lucius Pharmaceuticals had more than 200 generic drug varieties, covering multiple therapeutic areas such as anti-tumor drugs, cardiovascular drugs, hematological drugs, diabetes drugs, dermatological drugs, men's health drugs, and anti-aging drugs. Among them, 54 anticancer drugs have been approved for marketing.

In terms of quality certification, in October 2023, the World Health Organization (WHO) conducted a comprehensive assessment of Lucius Pharmaceuticals' factory and confirmed that its factory fully complies with WHO standards. Its production environment also complies with the GMP standards of Laos, the European Union, the United States, and China. At present, the company's business has expanded to 12 countries, including Thailand, Indonesia, Cambodia, Vietnam, the Philippines, Singapore, Malaysia, Turkey, Japan, and China.

About LuciTir(Tirzepatide) Injection

Indications

LuciTir(Tirzepatide) is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor. It can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and it also helps with glycemic control and durable weight loss in adults with type 2 diabetes mellitus and obesity.

LuciTir(Tirzepatide) can also be used to reduce excess body weight in adults with overweight or obesity and to maintain weight loss over the long term.

Dosage and Administration

LuciTir(Tirzepatide) is administered by subcutaneous injection once weekly.

The recommended starting dose is 2.5 mg once weekly for 4 weeks;

After 4 weeks, the dose is increased to 5 mg once weekly.

Thereafter, based on the patient's treatment response and tolerability, the dose may be gradually adjusted in increments of 2.5 mg at intervals of at least 4 weeks, up to a maximum recommended dose of 15 mg once weekly.

Lucius provides this drug in multiple strengths of prefilled injection pens, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, making it convenient for patients to self-inject at home.

Common Adverse Reactions

The most common adverse reactions of LuciTir(Tirzepatide) are mainly gastrointestinal symptoms, including nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, etc. Injection site reactions, fatigue, allergic reactions, eructation, hair loss, and gastroesophageal reflux disease may also occur. Clinical data show that the incidence of nausea with LuciTir(Tirzepatide) is approximately 17%–22%, and most patients experience only mild to moderate discomfort.

Special reminder: LuciTir(Tirzepatide) can cause thyroid C-cell tumors in rats. It is not yet known whether the drug causes thyroid C-cell tumors in humans, including medullary thyroid carcinoma (MTC). Therefore, patients with a personal or family history of MTC and patients with type 2 multiple endocrine neoplasia syndrome (MEN2) are contraindicated for this product-22. Patients should use this drug under the guidance of a professional physician and strictly follow the instructions for dose escalation to reduce the risk of gastrointestinal adverse reactions.

Lao Lucius Pharmaceutical reminds consumers: when purchasing products, be sure to use formal channels and rely on the official anti-counterfeiting query website cc.wkfw318.com (one "w"). Do not trust counterfeit websites, jointly resist counterfeit and inferior products, and safeguard your own medication safety.